The need for systematic therapeutic drug monitoring of isoniazid in tuberculosis: A real-world study.

International Journal of Antimicrobial Agents 2026 Open access

Read full text
Authors: Marine Chancel, Youssef Bennis, Sandra Bodeau, Anne‐Sophie Lemaire‐Hurtel, Jean‐Philippe Lanoix, Claire Andréjak
DOI: 10.1016/j.ijantimicag.2026.107827
Cited by: 1
References: 21

Abstract

Objectives Isoniazid is a primary first-line antituberculosis agent, exhibiting concentration-dependent bactericidal effect while also posing a risk of hepatotoxicity. Therapeutic drug monitoring could optimize exposure but remains underused. This study aimed to assess isoniazid pharmacokinetic variability in real-world settings and the proportion of patients achieving therapeutic concentrations. Methods We conducted a retrospective, single-centre study of adult tuberculosis patients receiving standard first-line therapy (isoniazid, rifampicin, pyrazinamide, ethambutol). Patients underwent fasted-state isoniazid monitoring via a 4-point limited-sampling protocol. We calculated AUC 0–24h and acetylation status (rapid: half-life

Fields of Study & Subjects

Drug-Induced Hepatotoxicity and Protection Tuberculosis Research and Epidemiology Drug-Induced Ocular Toxicity

Publication details

Journal / source
International Journal of Antimicrobial Agents
Publisher
Elsevier BV
Volume
67
Issue
8
Pages
107827–107827
Publication date
1 May 2026
Language
EN